OKYO Pharma Ltd
OKYO Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.49
KIRA · Stoqly’s AI analyst, in plain words
- OKYO Pharma Ltd lost $8.9M in fiscal 2026.
- Free cash flow was −$5.9M in fiscal 2026, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$8.9M
Free cash flow
−$5.9M
Operating margin
—
OKYO Pharma Ltd in 30 seconds · fiscal 2026
Does it make a profit?
−$8.9M
No. It lost money last year.
What OKYO Pharma Ltd does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 20-F · Jul 20, 2026
- Legal name
- OKYO Pharma Ltd
- CIK
- 0001849296
OKYO Pharma Ltd · OKYO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$5.4M | −$13.3M | −$16.8M | −$4.7M | −$8.9M |
| Diluted EPS | −$0.36 | −$0.61 | −$0.57 | −$0.12 | −$0.24 |
| Cash | |||||
| Cash from operations | −$5.5M | −$7.7M | −$9.5M | −$1.8M | −$5.9M |
| Capital expenditure | $0.0M | $0.0M | — | $0.0M | $0.0M |
| Free cash flow | −$5.5M | −$7.7M | — | −$1.8M | −$5.9M |
| Share count change | 45.5% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $2.7M | $4.0M | $0.8M | $1.6M | $14.6M |
| Debt incl. finance leases | — | — | — | $2.7M | — |
| Shareholders' equity | $2.9M | −$2.1M | −$5.9M | −$5.5M | $12.3M |
| Current ratio | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Returns and quality | |||||
| Return on equity | −131.4% | −2,968.4% | — | — | −263.8% |
| Return on tangible equity | −184.3% | — | — | — | −72.6% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
OKYO Pharma Ltd · OKYO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.49 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001849296). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.